Diferencia entre revisiones de «Template:ICH Treatment»
(Convert BP control, TXA, and desmopressin dosing to MedicationDose templates for SMW integration) |
|||
| Línea 17: | Línea 17: | ||
* | *{{MedicationDose|drug=Nicardipine|dose=5-15 mg/hr IV, titrate by 2.5 mg q5min|route=IV drip|context=BP control in ICH|indication={{PAGENAME}}|population=Adult|notes=Titrate down to 3 mg/hr maintenance once target achieved}} | ||
* | *{{MedicationDose|drug=Labetalol|dose=20 mg IV bolus, repeat q3-5 min; then 1-8 mg/min drip|route=IV|context=BP control in ICH|indication={{PAGENAME}}|population=Adult}} | ||
===Reverse coagulopathy=== | ===Reverse coagulopathy=== | ||
[[File:Harobr tICH algorithm.png|thumb|Example ''traumatic'' ICH coagulopathy reversal algorithm.]] | [[File:Harobr tICH algorithm.png|thumb|Example ''traumatic'' ICH coagulopathy reversal algorithm.]] | ||
*See [[anticoagulant reversal for life-threatening bleeds]] if on a known anticoagulant (e.g. [[heparin]], [[coumadin]], [[rivaroxaban]]) | *See [[anticoagulant reversal for life-threatening bleeds]] if on a known anticoagulant (e.g. [[heparin]], [[coumadin]], [[rivaroxaban]]) | ||
* | *{{MedicationDose|drug=Tranexamic acid|dose=1g IV (within 3 hrs of event), then 1g over 8 hrs|route=IV|context=Coagulopathy reversal in ICH|indication={{PAGENAME}}|population=Adult}} <ref>[[EBQ:CRASH-3 Trial|Crash-3 Trial]]</ref> | ||
====Antiplatelet Reversal==== | ====Antiplatelet Reversal==== | ||
''Includes [[aspirin]], [[prasugrel]], [[clopidogrel]]'' | ''Includes [[aspirin]], [[prasugrel]], [[clopidogrel]]'' | ||
*Consider | *Consider {{MedicationDose|drug=Desmopressin|dose=0.3 mcg/kg IV|route=IV|context=Antiplatelet reversal in ICH|indication={{PAGENAME}}|population=Adult}} | ||
*Platelet transfusion | *Platelet transfusion | ||
**No known thrombocytopenia: ''increases'' mortality; do '''NOT''' give<ref>[[EBQ:Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial|(PATCH trial)]]</ref> | **No known thrombocytopenia: ''increases'' mortality; do '''NOT''' give<ref>[[EBQ:Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial|(PATCH trial)]]</ref> | ||
**Known or diagnosed thrombocytopenia: consider if platelets <50,000 | **Known or diagnosed thrombocytopenia: consider if platelets <50,000 | ||
***Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes | ***Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes | ||
Revisión actual - 22:32 20 mar 2026
Elevating head of bed
- 30 degree elevation will help decrease ICP by increasing venous outflow[1]
Seizure Prophylaxis and Treatment
- Prophylactic antiepileptics not recommended[2]
- Continuous EEG monitoring probably indicated in ICH patients with depressed mental status that is out of proportion fo degree of brain injury[3]
- Antiepileptics indicated for clinical seizures or seizures on EEG in patients with altered mental status[4]
Blood Pressure
- Rapid SBP lowering <140 has been advocated with early research showing improved functional outcome[5], but more recent work has found no difference between SBP <140 and <180[6]
- SBP >200 or MAP >150
- Consider aggressive reduction w/ continuous IV infusion
- SBP >180 or MAP >130 and evidence or suspicion of elevated ICP
- Consider reducing BP using intermittent or continuous IV meds to keep CPP >60-80
- SBP >180 or MAP >130 and NO evidence or suspicion of elevated ICP
- Consider modest reduction of BP (e.g. MAP of 110 or target BP of 160/90)
- Nicardipine 5-15 mg/hr IV, titrate by 2.5 mg q5min IV drip — Titrate down to 3 mg/hr maintenance once target achieved
- Labetalol 20 mg IV bolus, repeat q3-5 min; then 1-8 mg/min drip IV
Reverse coagulopathy
- See anticoagulant reversal for life-threatening bleeds if on a known anticoagulant (e.g. heparin, coumadin, rivaroxaban)
- Tranexamic acid 1g IV (within 3 hrs of event), then 1g over 8 hrs IV [7]
Antiplatelet Reversal
Includes aspirin, prasugrel, clopidogrel
- Consider Desmopressin 0.3 mcg/kg IV IV
- Platelet transfusion
- No known thrombocytopenia: increases mortality; do NOT give[8]
- Known or diagnosed thrombocytopenia: consider if platelets <50,000
- Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes
- ↑ http://stroke.ahajournals.org/content/38/6/2001.full
- ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
- ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
- ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
- ↑ Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368:2355-2365.
- ↑ Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016; 1-11. [Epub ahead of print].
- ↑ Crash-3 Trial
- ↑ (PATCH trial)
